SODIUM P.A.S. Drug Patent Profile
✉ Email this page to a colleague
When do Sodium P.a.s. patents expire, and what generic alternatives are available?
Sodium P.a.s. is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in SODIUM P.A.S. is aminosalicylate sodium. There are three drug master file entries for this compound. Additional details are available on the aminosalicylate sodium profile page.
Summary for SODIUM P.A.S.
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Clinical Trials: | 3,629 |
Patent Applications: | 6 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SODIUM P.A.S. at DailyMed |
Recent Clinical Trials for SODIUM P.A.S.
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sahlgrenska University Hospital, Sweden | Phase 4 |
Harvard Medical School (HMS and HSDM) | Phase 4 |
Swedish Heart Lung Foundation | Phase 4 |
US Patents and Regulatory Information for SODIUM P.A.S.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lannett | SODIUM P.A.S. | aminosalicylate sodium | TABLET;ORAL | 080138-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |